Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Harmony Biosciences Holdings, Inc. (HRMY)
USD34.47
-1.08 (-3.02%)
US NASDAQ Healthcare Biotechnology
Address
630 West Germantown Pike 19462
Plymouth Meeting, PA, US
Plymouth Meeting, PA, US
CEO
Jeffrey Dayno
Website
harmonybiosciences.com
IPO
2020-08-19
CIK 1802665 ISIN US4131971040
Description
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD34.47
-1.08 (-3.02%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
845.6K
Beta
0.94
Float Shares
50.49M
Free Float %
87.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10% | -5.52% | +3.79% | -16.27% | -12.07% | -19.43% | -12.28% | -17.49% | +15.52% | -18.54% | -18.54% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
34.47
Low
31.00
-10.1%
Consensus
46.80
+35.8%
Median
46.00
+33.5%
High
62.00
+79.9%
DCF (Unlevered)
120.52
+249.7%
DCF (Levered)
173.54
+403.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
55% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 3 |
42.33
+22.8%
|
| Last Year | 10 |
44.70
+29.7%
|
| All Time | 19 |
46.26
+34.2%
|
Quality scores
Altman Z-Score
4.90
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
8 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+21.5% ★ Q1'26: +16.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+8.0% Q1'26: -29.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+31.7% ★ Q1'26: +12.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+26.5% ★ Q1'26: +19.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+50.7% ★ Q1'26: +29.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.2% ★ Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.94× ★ Q1'26: 1.06× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 5 EPS Ana. |
Dec 2027 8 Rev. Ana. 6 EPS Ana. |
Dec 2028 9 Rev. Ana. 9 EPS Ana. |
Dec 2029 4 Rev. Ana. 3 EPS Ana. |
Dec 2030 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
159.74M
est: 155.21M (+2.9%)
|
305.44M
est: 303.77M (+0.6%)
|
437.86M
est: 436.79M (+0.2%)
|
582.02M
est: 656.11M (-11.3%)
|
714.73M
est: 714.38M (+0.0%)
|
868.45M
est: 865.06M (+0.4%)
|
1.01B
913.15M – 1.02B
+17.3% YoY
|
1.15B
953.60M – 1.28B
+13.3% YoY
|
1.26B
1.25B – 1.28B
+9.7% YoY
|
1.47B
1.32B – 1.57B
+16.6% YoY
|
1.26B
1.14B – 1.35B
-14.2% YoY
|
| EBITDA |
1.51M
est: 40.83M (-96.3%)
|
80.46M
est: 202.64M (-60.3%)
|
146.87M
est: 101.06M (+45.3%)
|
221.51M
est: 208.77M (+6.1%)
|
233.41M
est: 227.31M (+2.7%)
|
255.05M
est: 275.26M (-7.3%)
|
322.81M
290.56M – 325.97M
+17.3% YoY
|
365.82M
303.43M – 407.90M
+13.3% YoY
|
401.43M
396.23M – 406.63M
+9.7% YoY
|
468.16M
421.39M – 500.95M
+16.6% YoY
|
401.56M
361.44M – 429.69M
-14.2% YoY
|
| EBIT |
-8.72M
est: 32.93M (-126.5%)
|
61.62M
est: 259.06M (-76.2%)
|
123.48M
est: 113.60M (+8.7%)
|
197.15M
est: 214.85M (-8.2%)
|
209.30M
est: 233.93M (-10.5%)
|
229.71M
est: 283.27M (-18.9%)
|
332.21M
299.02M – 335.46M
+17.3% YoY
|
376.47M
312.27M – 419.78M
+13.3% YoY
|
413.12M
407.77M – 418.47M
+9.7% YoY
|
481.79M
433.66M – 515.54M
+16.6% YoY
|
413.25M
371.97M – 442.20M
-14.2% YoY
|
| Net Income |
-36.94M
est: -33.85M (-9.1%)
|
34.60M
est: 121.44M (-71.5%)
|
181.47M
est: 58.46M (+210.4%)
|
128.85M
est: 114.99M (+12.1%)
|
145.49M
est: 135.32M (+7.5%)
|
158.69M
est: 191.07M (-16.9%)
|
222.58M
156.81M – 253.26M
+16.5% YoY
|
266.91M
198.49M – 301.25M
+19.9% YoY
|
302.49M
83.73M – 357.59M
+13.3% YoY
|
371.99M
323.68M – 405.87M
+23.0% YoY
|
317.86M
276.58M – 346.81M
-14.6% YoY
|
| SGA |
95.57M
est: 63.45M (+50.6%)
|
132.03M
est: 124.19M (+6.3%)
|
163.30M
est: 153.05M (+6.7%)
|
192.69M
est: 230.84M (-16.5%)
|
221.27M
est: 251.34M (-12.0%)
|
272.05M
est: 304.35M (-10.6%)
|
356.92M
321.27M – 360.42M
+17.3% YoY
|
404.48M
335.50M – 451.01M
+13.3% YoY
|
443.86M
438.11M – 449.60M
+9.7% YoY
|
517.63M
465.92M – 553.90M
+16.6% YoY
|
444.00M
399.64M – 475.10M
-14.2% YoY
|
| EPS |
-1.12
est: -0.59 (-91.5%)
|
0.60
est: 0.64 (-6.3%)
|
3.07
est: 2.79 (+10.1%)
|
2.17
est: 1.98 (+9.3%)
|
2.56
est: 2.36 (+8.7%)
|
2.76
est: 3.20 (-13.8%)
|
3.50
2.68 – 4.33
+9.2% YoY
|
4.12
3.39 – 5.15
+17.8% YoY
|
4.81
1.43 – 6.11
+16.7% YoY
|
6.35
5.53 – 6.93
+32.1% YoY
|
5.43
4.72 – 5.92
-14.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
342.60M
OE per share TTM
5.85
Owner's Yield
18.86%
Maintenance CapEx ratio
0.49%
Maint CapEx / Avg PPE
0.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
75
Total invested
125.21M
Insider transactions (90d)
0
Beneficial owners (>5%)
21
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Antonio J. Gracias | 11.22M | 19.20% | 4.2K | 11.22M | 4.2K | 11.22M | IN | Delaware | 2022-02-10 | ↗ |
| 2 | Juan A. Sabater | 11.22M | 19.20% | 3.0K | 11.22M | 3.0K | 11.22M | IN | Delaware | 2022-02-10 | ↗ |
| 3 | IV-B | 11.22M | 19.20% | — | 11.22M | — | 11.22M | PN | Delaware | 2022-02-10 | ↗ |
| 4 | Valor Equity Associates IV L.P. | 11.22M | 19.20% | — | 11.22M | — | 11.22M | HC | Delaware | 2022-02-10 | ↗ |
| 5 | Valor Equity Capital IV LLC | 11.22M | 19.20% | — | 11.22M | — | 11.22M | HC | Delaware | 2022-02-10 | ↗ |
| 6 | Valor IV Pharma Holdings, LLC | 11.22M | 19.20% | — | 11.22M | — | 11.22M | OO | Delaware | 2022-02-10 | ↗ |
| 7 | Valor Management L.P. | 11.22M | 19.20% | — | 11.22M | — | 11.22M | HC | Delaware | 2022-02-10 | ↗ |
| 8 | Marshman Fund Trust II | 10.65M | 18.70% | 10.65M | — | 10.65M | — | OO | Illinois | 2021-01-29 | ↗ |
| 9 | Harmony Biosciences Holdings, Inc. | 7.59M | 13.13% | — | 7.59M | — | — | CO | — | 2023-08-24 | ↗ |
| 10 | Xylophone Acquisition Corp. | 7.59M | 13.13% | — | 7.59M | — | — | CO | — | 2023-08-24 | ↗ |
| 11 | (1) BlackRock, Inc. | 6.13M | 10.20% | 5.97M | — | 6.13M | — | HC | Delaware | 2023-10-06 | ↗ |
| 12 | HBM Healthcare Investments (Cayman) Ltd. | 4.55M | 7.80% | 4.55M | — | 4.55M | — | CO | Cayman Islands, British West Indies | 2022-02-11 | ↗ |
| 13 | Vivo Capital VIII, LLC | 4.30M | 7.40% | 4.30M | — | 4.30M | — | OO | — | 2022-02-11 | ↗ |
| 14 | 6.6% (1) | 3.75M | 6.60% | 3.75M | — | 3.75M | — | CO | Denmark | 2020-09-04 | ↗ |
| 15 | Corey Goodman | 2.74M | 4.70% | — | 2.74M | — | 2.74M | IN | — | 2022-02-14 | ↗ |
| 16 | Robert Adelman | 2.74M | 4.70% | — | 2.74M | — | 2.74M | IN | — | 2022-02-14 | ↗ |
| 17 | venBio Global Strategic Fund II, L.P. | 2.74M | 4.70% | — | 2.74M | — | 2.74M | PN | — | 2022-02-14 | ↗ |
| 18 | venBio Global Strategic GP II, L.P. | 2.74M | 4.70% | — | 2.74M | — | 2.74M | PN | — | 2022-02-14 | ↗ |
| 19 | Novo Holdings A/S | 2.42M | 4.20% | 2.42M | — | 2.42M | — | CO | Denmark | 2021-05-21 | ↗ |
| 20 | Vivo Opportunity, LLC | 541.4K | 0.90% | 541.4K | — | 541.4K | — | OO | — | 2022-02-11 | ↗ |
| 21 | Vivo Capital IX, LLC. | 42.7K | 0.10% | 42.7K | — | 42.7K | — | OO | Delaware | 2020-09-01 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
75
-254 vs prev Q
New positions
9
Closed positions
256
Increased
34
Reduced
28
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 7.09M +162.7K (+2.3%) | 265.26M +74.4M (+39.0%) | 12.12% +0.073 pp | 0.00% +0.001 pp | USD38.38 -2.5% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 4.81M -283.8K (-5.6%) | 180.12M +39.6M (+28.2%) | 8.23% -0.637 pp | 0.00% +0.001 pp | USD36.66 +2.1% | 21 qtrs — |
| 3 | FMR LLC | 3.11M -734.2K (-19.1%) | 116.48M +10.5M (+9.9%) | 5.32% -1.370 pp | 0.01% +0.000 pp | USD37.51 -0.2% | 22 qtrs — |
| 4 | AMERICAN CENTURY COMPANIES INC | 1.84M +172.1K (+10.3%) | 68.92M +22.9M (+49.8%) | 3.15% +0.245 pp | 0.03% +0.011 pp | USD34.27 +9.2% | 22 qtrs — |
| 5 | DIMENSIONAL FUND ADVISORS LP | 1.83M +139.1K (+8.2%) | 68.51M +21.9M (+46.9%) | 3.13% +0.188 pp | 0.01% +0.004 pp | USD36.38 +2.9% | 18 qtrs — |
| 6 | STATE STREET CORP | 1.66M +8.2K (+0.5%) | 62.19M +16.6M (+36.5%) | 2.84% -0.035 pp | 0.00% +0.001 pp | USD36.96 +1.2% | 21 qtrs — |
| 7 | LSV ASSET MANAGEMENT | 1.66M +62.2K (+3.9%) | 62.01M +18.1M (+41.1%) | 2.83% +0.059 pp | 0.14% +0.038 pp | USD33.16 +12.8% | 9 qtrs — |
| 8 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.49M +196.2K (+15.1%) | 55.82M +20.1M (+56.3%) | 2.55% +0.297 pp | 0.03% +0.010 pp | USD33.09 +13.1% | 6 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.27M +12.3K (+1.0%) | 47.55M +12.9M (+37.1%) | 2.17% -0.016 pp | 0.00% +0.001 pp | USD34.34 +9.0% | 22 qtrs — |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 1.07M -66.6K (-5.9%) | 40.06M +8.7M (+27.8%) | 1.83% -0.148 pp | 0.06% +0.021 pp | USD33.33 +12.3% | 19 qtrs — |
| 11 | SG AMERICAS SECURITIES, LLC | 961.7K +938.8K (+4,102.4%) | 35.99M +35.4M (+5,603.0%) | 1.64% +1.605 pp | 0.05% +0.044 pp | USD37.34 +0.2% | 10 qtrs — |
| 12 | MORGAN STANLEY | 817.5K -30.4K (-3.6%) | 30.59M +7.2M (+30.9%) | 1.40% -0.077 pp | 0.00% +0.000 pp | USD35.73 +4.7% | 22 qtrs — |
| 13 | AQR CAPITAL MANAGEMENT LLC | 813.9K +458.3K (+128.9%) | 30.46M +20.7M (+210.8%) | 1.39% +0.773 pp | 0.02% +0.010 pp | USD34.67 +7.9% | 15 qtrs — |
| 14 | BOSTON PARTNERS | 708.9K -45.0K (-6.0%) | 26.37M +5.7M (+27.4%) | 1.21% -0.099 pp | 0.03% +0.006 pp | USD30.80 +21.5% | 3 qtrs — |
| 15 | GOLDMAN SACHS GROUP INC | 569.4K -77.3K (-12.0%) | 21.31M +3.5M (+19.5%) | 0.97% -0.151 pp | 0.00% +0.000 pp | USD32.37 +15.6% | 22 qtrs — |
| 16 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 541.3K -29.3K (-5.1%) | 20.25M +4.5M (+28.8%) | 0.93% -0.067 pp | 0.01% +0.002 pp | USD35.27 +6.1% | 22 qtrs — |
| 17 | BNP PARIBAS ARBITRAGE, SNC | 525.1K +130.0K (+32.9%) | 19.65M +8.8M (+80.4%) | 0.90% +0.211 pp | 0.01% +0.003 pp | USD32.58 +14.9% | 5 qtrs — |
| 18 | NOMURA HOLDINGS INC | 510.0K +72.9K (+16.7%) | 19.09M +7.0M (+58.4%) | 0.87% +0.112 pp | 0.03% +0.007 pp | USD32.67 +14.5% | 8 qtrs — |
| 19 | ARMISTICE CAPITAL, LLC | 500.0K +500.0K (+100.0%) | 18.71M +18.7M (+100.0%) | 0.86% +0.855 pp | 0.22% +0.223 pp | USD37.42 +0.0% | 1 qtrs NEW |
| 20 | VENBIO PARTNERS LLC | 489.2K +— (+0.0%) | 18.31M +4.8M (+35.8%) | 0.84% -0.015 pp | 8.46% +0.821 pp | USD33.90 +10.4% | 22 qtrs — |
| 21 | DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN | 459.1K +193.4K (+72.8%) | 17.18M +9.9M (+134.6%) | 0.79% +0.323 pp | 0.01% +0.008 pp | USD31.75 +17.9% | 3 qtrs — |
| 22 | INVESCO LTD. | 450.8K +47.5K (+11.8%) | 16.87M +5.8M (+51.8%) | 0.77% +0.069 pp | 0.00% +0.001 pp | USD37.67 -0.7% | 19 qtrs — |
| 23 | CITADEL ADVISORS LLC | 420.4K +352.4K (+518.1%) | 15.73M +13.9M (+739.3%) | 0.72% +0.601 pp | 0.00% +0.002 pp | USD35.82 +4.5% | 22 qtrs — |
| 24 | NORTHERN TRUST CORP | 418.9K -13.8K (-3.2%) | 15.68M +3.7M (+31.4%) | 0.72% -0.037 pp | 0.00% +0.001 pp | USD34.80 +7.5% | 21 qtrs — |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 418.0K -38.4K (-8.4%) | 15.64M +3.1M (+24.3%) | 0.71% -0.079 pp | 0.00% +0.000 pp | USD35.38 +5.8% | 21 qtrs — |
| 26 | 683 CAPITAL MANAGEMENT, LLC | 415.0K +133.0K (+47.2%) | 15.53M +7.8M (+99.8%) | 0.71% +0.219 pp | 0.68% +0.270 pp | USD34.99 +6.9% | 12 qtrs — |
| 27 | ALGERT GLOBAL LLC | 359.8K +91.2K (+34.0%) | 13.46M +6.1M (+81.9%) | 0.62% +0.148 pp | 0.21% +0.086 pp | USD34.65 +8.0% | 16 qtrs — |
| 28 | DEUTSCHE BANK AG\ | 344.2K -81.5K (-19.2%) | 12.88M +1.1M (+9.8%) | 0.59% -0.152 pp | 0.00% +0.000 pp | USD30.49 +22.7% | 21 qtrs — |
| 29 | JANUS HENDERSON GROUP PLC | 322.3K +305.9K (+1,865.0%) | 12.06M +11.6M (+2,569.8%) | 0.55% +0.523 pp | 0.01% +0.005 pp | USD37.23 +0.5% | 22 qtrs — |
| 30 | MAN GROUP PLC | 306.7K +29.7K (+10.7%) | 11.48M +3.8M (+50.3%) | 0.52% +0.043 pp | 0.02% +0.006 pp | USD35.05 +6.8% | 18 qtrs — |
| 31 | TREXQUANT INVESTMENT LP | 299.4K +27.4K (+10.1%) | 11.20M +3.7M (+49.5%) | 0.51% +0.039 pp | 0.10% +0.023 pp | USD30.85 +21.3% | 5 qtrs — |
| 32 | UBS GROUP AG | 297.2K -205.9K (-40.9%) | 11.12M -2.7M (-19.8%) | 0.51% -0.367 pp | 0.00% 0.000 pp | USD29.98 +24.8% | 22 qtrs — |
| 33 | TIETON CAPITAL MANAGEMENT, LLC | 297.1K -1.5K (-0.5%) | 11.12M +2.9M (+35.1%) | 0.51% -0.011 pp | 3.80% +0.946 pp | USD30.78 +21.6% | 3 qtrs — |
| 34 | PACER ADVISORS, INC. | 290.4K -72.6K (-20.0%) | 10.87M +862.2K (+8.6%) | 0.50% -0.135 pp | 0.03% +0.003 pp | USD32.92 +13.7% | 11 qtrs — |
| 35 | TANG CAPITAL MANAGEMENT LLC | 290.3K +9.1K (+3.2%) | 10.86M +3.1M (+40.2%) | 0.50% +0.007 pp | 0.54% +0.238 pp | USD45.78 -18.3% | 16 qtrs — |
| 36 | CAPITAL MANAGEMENT CORP /VA | 281.7K -41.2K (-12.8%) | 10.54M +1.6M (+18.5%) | 0.48% -0.080 pp | 1.73% +0.329 pp | USD33.15 +12.9% | 8 qtrs — |
| 37 | ROYCE & ASSOCIATES LP | 278.2K +196.4K (+240.3%) | 10.41M +8.2M (+362.0%) | 0.48% +0.334 pp | 0.11% +0.083 pp | USD36.62 +2.2% | 19 qtrs — |
| 38 | CX INSTITUTIONAL | 275.8K +45.4K (+19.7%) | 10.32M +4.0M (+62.5%) | 0.47% +0.071 pp | 0.31% +0.115 pp | USD32.67 +14.5% | 4 qtrs — |
| 39 | BANK OF AMERICA CORP /DE/ | 275.1K +84.6K (+44.5%) | 10.29M +5.0M (+96.1%) | 0.47% +0.139 pp | 0.00% +0.000 pp | USD34.09 +9.8% | 22 qtrs — |
| 40 | VICTORY CAPITAL MANAGEMENT INC | 272.6K +36.9K (+15.7%) | 10.20M +3.7M (+57.0%) | 0.47% +0.056 pp | 0.01% +0.002 pp | USD33.18 +12.8% | 17 qtrs — |
| 41 | BANK OF NEW YORK MELLON CORP | 264.4K -269.0 (-0.1%) | 9.89M +2.6M (+35.6%) | 0.45% -0.008 pp | 0.00% +0.000 pp | USD38.94 -3.9% | 21 qtrs — |
| 42 | FEDERATED HERMES, INC. | 263.8K -34.4K (-11.5%) | 9.87M +1.7M (+20.1%) | 0.45% -0.068 pp | 0.02% +0.002 pp | USD33.01 +13.4% | 16 qtrs — |
| 43 | PRINCIPAL FINANCIAL GROUP INC | 252.6K +21.6K (+9.4%) | 9.45M +3.1M (+48.5%) | 0.43% +0.030 pp | 0.00% +0.002 pp | USD39.91 -6.2% | 17 qtrs — |
| 44 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 249.1K +17.2K (+7.4%) | 9.32M +2.9M (+45.9%) | 0.43% +0.023 pp | 0.02% +0.004 pp | USD32.68 +14.5% | 6 qtrs — |
| 45 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 248.1K +62.3K (+33.5%) | 9.28M +4.2M (+81.3%) | 0.42% +0.101 pp | 0.03% +0.012 pp | USD34.47 +8.6% | 17 qtrs — |
| 46 | BRIDGE CITY CAPITAL, LLC | 237.1K -22.8K (-8.8%) | 8.87M +1.7M (+23.8%) | 0.41% -0.047 pp | 2.61% +0.695 pp | USD33.30 +12.4% | 6 qtrs — |
| 47 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 234.9K +116.0 (+0.0%) | 8.79M +2.3M (+35.9%) | 0.40% -0.007 pp | 0.01% +0.004 pp | USD31.99 +17.0% | 5 qtrs — |
| 48 | MILLENNIUM MANAGEMENT LLC | 231.7K +27.2K (+13.3%) | 8.67M +3.0M (+53.8%) | 0.40% +0.040 pp | 0.00% +0.001 pp | USD29.42 +27.2% | 22 qtrs — |
| 49 | BRIDGEWATER ASSOCIATES, LP | 228.5K +17.0K (+8.0%) | 8.55M +2.7M (+46.7%) | 0.39% +0.023 pp | 0.03% +0.008 pp | USD28.29 +32.3% | 2 qtrs — |
| 50 | JANE STREET GROUP, LLC | 221.6K +108.9K (+96.7%) | 8.29M +5.2M (+167.1%) | 0.38% +0.183 pp | 0.00% +0.001 pp | USD32.41 +15.5% | 16 qtrs — |
| 51 | AMERIPRISE FINANCIAL INC | 221.5K +127.3K (+135.2%) | 8.29M +5.7M (+219.4%) | 0.38% +0.215 pp | 0.00% +0.001 pp | USD39.70 -5.7% | 17 qtrs — |
| 52 | PICTET ASSET MANAGEMENT HOLDING SA | 207.4K -9.9K (-4.5%) | 7.86M +1.9M (+30.9%) | 0.35% -0.023 pp | 0.01% +0.002 pp | USD32.14 +16.4% | 4 qtrs — |
| 53 | TWO SIGMA INVESTMENTS, LP | 207.0K -18.3K (-8.1%) | 7.74M +1.5M (+24.7%) | 0.35% -0.038 pp | 0.01% +0.002 pp | USD34.66 +8.0% | 17 qtrs — |
| 54 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 203.5K +203.5K (+100.0%) | 7.61M +7.6M (+100.0%) | 0.35% +0.348 pp | 0.01% +0.013 pp | USD37.42 +0.0% | 1 qtrs NEW |
| 55 | JPMORGAN CHASE & CO | 199.4K +25.4K (+14.6%) | 7.46M +2.7M (+55.6%) | 0.34% +0.038 pp | 0.00% +0.000 pp | USD34.78 +7.6% | 22 qtrs — |
| 56 | ALLIANCEBERNSTEIN L.P. | 169.7K +630.0 (+0.4%) | 6.35M +1.7M (+36.3%) | 0.29% -0.004 pp | 0.00% +0.001 pp | USD34.85 +7.4% | 19 qtrs — |
| 57 | FIRST TRUST ADVISORS LP | 155.4K +42.1K (+37.2%) | 5.81M +2.7M (+86.3%) | 0.27% +0.069 pp | 0.00% +0.002 pp | USD34.25 +9.3% | 17 qtrs — |
| 58 | HRT FINANCIAL LP | 155.1K +155.1K (+100.0%) | 5.80M +5.8M (+100.0%) | 0.27% +0.265 pp | 0.02% +0.018 pp | USD37.42 +0.0% | 1 qtrs NEW |
| 59 | CITIGROUP INC | 154.5K -23.5K (-13.2%) | 5.78M +875.1K (+17.8%) | 0.26% -0.046 pp | 0.00% +0.000 pp | USD34.15 +9.6% | 21 qtrs — |
| 60 | WALLEYE CAPITAL LLC | 141.8K +141.8K (+100.0%) | 5.30M +5.3M (+100.0%) | 0.24% +0.243 pp | 0.02% +0.016 pp | USD37.42 +0.0% | 1 qtrs NEW |
| 61 | UBS ASSET MANAGEMENT AMERICAS INC | 139.9K +70.1K (+100.3%) | 5.24M +3.3M (+171.9%) | 0.24% +0.118 pp | 0.00% +0.001 pp | USD35.31 +6.0% | 17 qtrs — |
| 62 | HUDSON BAY CAPITAL MANAGEMENT LP | 138.5K +138.5K (+100.0%) | 5.18M +5.2M (+100.0%) | 0.24% +0.237 pp | 0.02% +0.017 pp | USD37.42 +0.0% | 1 qtrs NEW |
| 63 | HILLSDALE INVESTMENT MANAGEMENT INC. | 137.4K +— (+0.0%) | 5.14M +1.4M (+35.8%) | 0.24% -0.004 pp | 0.14% +0.028 pp | USD41.74 -10.3% | 13 qtrs — |
| 64 | VALOR MANAGEMENT LLC | 117.1K -1.2M (-90.8%) | 4.38M -30.6M (-87.5%) | 0.20% -2.006 pp | 7.95% -43.951 pp | USD42.64 -12.2% | 17 qtrs — |
| 65 | RHUMBLINE ADVISERS | 116.9K -6.1K (-4.9%) | 4.38M +985.9K (+29.1%) | 0.20% -0.014 pp | 0.00% +0.001 pp | USD37.25 +0.5% | 19 qtrs — |
| 66 | BARCLAYS PLC | 115.5K +38.6K (+50.2%) | 4.32M +1.2M (+40.5%) | 0.20% +0.064 pp | 0.00% +0.000 pp | USD36.26 +3.2% | 16 qtrs — |
| 67 | D. E. SHAW & CO., INC. | 114.3K -78.3K (-40.7%) | 4.28M -1.0M (-19.4%) | 0.20% -0.140 pp | 0.00% -0.001 pp | USD42.31 -11.6% | 16 qtrs — |
| 68 | LEGAL & GENERAL GROUP PLC | 107.2K -5.8K (-5.1%) | 4.01M +896.7K (+28.8%) | 0.18% -0.013 pp | 0.00% +0.000 pp | USD39.63 -5.6% | 21 qtrs — |
| 69 | TWO SIGMA ADVISERS, LP | 104.4K +64.6K (+162.2%) | 3.91M +2.8M (+256.0%) | 0.18% +0.109 pp | 0.01% +0.005 pp | USD39.16 -4.4% | 16 qtrs — |
| 70 | DENALI ADVISORS LLC | 97.8K -4.2K (-4.1%) | 3.66M +848.8K (+30.2%) | 0.17% -0.010 pp | 0.41% +0.089 pp | USD34.03 +10.0% | 7 qtrs — |
| 71 | HENNION & WALSH ASSET MANAGEMENT, INC. | 96.7K +10.3K (+11.9%) | 3.62M +1.2M (+51.9%) | 0.17% +0.015 pp | 0.12% +0.039 pp | USD35.72 +4.8% | 17 qtrs — |
| 72 | EDGESTREAM PARTNERS, L.P. | 90.8K +77.4K (+578.3%) | 3.40M +3.0M (+820.9%) | 0.16% +0.132 pp | 0.10% +0.085 pp | USD35.97 +4.0% | 4 qtrs — |
| 73 | WEDGE CAPITAL MANAGEMENT L L P/NC | 88.9K +88.9K (+100.0%) | 3.33M +3.3M (+100.0%) | 0.15% +0.152 pp | 0.06% +0.060 pp | USD37.42 +0.0% | 1 qtrs NEW |
| 74 | NEW YORK STATE COMMON RETIREMENT FUND | 88.3K -8.3K (-8.6%) | 3.31M +641.5K (+24.1%) | 0.15% -0.017 pp | 0.00% +0.001 pp | USD35.43 +5.6% | 21 qtrs — |
| 75 | BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC | 85.7K -60.5K (-41.4%) | 3.21M -821.7K (-20.4%) | 0.15% -0.108 pp | 0.02% -0.006 pp | USD27.56 +35.8% | 2 qtrs — |
| 76 | EMPOWERED FUNDS, LLC | 85.2K +30.9K (+56.9%) | 3.19M +1.7M (+113.0%) | 0.15% +0.051 pp | 0.03% +0.010 pp | USD34.72 +7.8% | 4 qtrs — |
| 77 | SWISS NATIONAL BANK | 85.1K +1.6K (+1.9%) | 3.18M +883.2K (+38.4%) | 0.15% +0.000 pp | 0.00% +0.001 pp | USD34.74 +7.7% | 19 qtrs — |
| 78 | IEQ CAPITAL, LLC | 84.1K +57.6K (+216.8%) | 3.15M +2.4M (+330.2%) | 0.14% +0.098 pp | 0.01% +0.007 pp | USD34.88 +7.3% | 4 qtrs — |
| 79 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 84.0K +84.0K (+100.0%) | 3.14M +3.1M (+100.0%) | 0.14% +0.144 pp | 0.00% +0.005 pp | USD37.42 +0.0% | 1 qtrs NEW |
| 80 | NUVEEN, LLC | 83.1K -3.1K (-3.6%) | 3.11M +734.4K (+30.9%) | 0.14% -0.008 pp | 0.00% +0.000 pp | USD33.19 +12.7% | 4 qtrs — |
| 81 | TFG ASSET MANAGEMENT GP LTD | 82.8K +82.8K (+100.0%) | 3.10M +3.1M (+100.0%) | 0.14% +0.142 pp | 0.65% +0.654 pp | USD37.42 +0.0% | 1 qtrs NEW |
| 82 | JACOBS LEVY EQUITY MANAGEMENT, INC | 82.3K -157.5K (-65.7%) | 3.08M -3.5M (-53.4%) | 0.14% -0.277 pp | 0.01% -0.014 pp | USD41.04 -8.8% | 14 qtrs — |
| 83 | CAPITAL FUND MANAGEMENT S.A. | 78.0K +28.1K (+56.3%) | 2.92M +1.5M (+112.2%) | 0.13% +0.047 pp | 0.01% +0.005 pp | USD32.98 +13.5% | 3 qtrs — |
| 84 | ZUCKERMAN INVESTMENT GROUP, LLC | 75.5K -47.8K (-38.8%) | 2.82M -573.2K (-16.9%) | 0.13% -0.085 pp | 0.25% -0.062 pp | USD27.56 +35.8% | 2 qtrs — |
| 85 | SEI INVESTMENTS CO | 73.6K +60.5K (+460.8%) | 2.76M +2.4M (+661.4%) | 0.13% +0.103 pp | 0.00% +0.002 pp | USD36.20 +3.4% | 4 qtrs — |
| 86 | HEDEKER WEALTH, LLC | 73.6K -6.7K (-8.3%) | 2.75M +541.4K (+24.5%) | 0.13% -0.014 pp | 0.58% +0.118 pp | USD33.15 +12.9% | 8 qtrs — |
| 87 | SCHRODER INVESTMENT MANAGEMENT GROUP | 72.7K +16.5K (+29.4%) | 2.74M +1.2M (+76.3%) | 0.12% +0.027 pp | 0.00% +0.001 pp | USD34.15 +9.6% | 14 qtrs — |
| 88 | STATE OF WISCONSIN INVESTMENT BOARD | 72.7K -1.9K (-2.5%) | 2.72M +664.2K (+32.3%) | 0.12% -0.006 pp | 0.01% +0.001 pp | USD34.42 +8.7% | 18 qtrs — |
| 89 | PRUDENTIAL FINANCIAL INC | 70.1K +12.0K (+20.6%) | 2.62M +1.0M (+63.7%) | 0.12% +0.019 pp | 0.00% +0.001 pp | USD35.65 +5.0% | 17 qtrs — |
| 90 | CONNORS INVESTOR SERVICES INC | 69.7K -2.0K (-2.8%) | 2.61M +633.0K (+32.0%) | 0.12% -0.006 pp | 0.22% +0.056 pp | USD34.40 +8.8% | 5 qtrs — |
| 91 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 69.5K +69.1K (+19,040.5%) | 2.60M +2.6M (+25,910.0%) | 0.12% +0.118 pp | 0.00% +0.003 pp | USD37.39 +0.1% | 3 qtrs — |
| 92 | ENGINEERS GATE MANAGER LP | 68.3K -21.8K (-24.2%) | 2.55M +71.8K (+2.9%) | 0.12% -0.040 pp | 0.03% +0.002 pp | USD30.43 +23.0% | 9 qtrs — |
| 93 | CRESSET ASSET MANAGEMENT, LLC | 67.4K +221.0 (+0.3%) | 2.52M +670.4K (+36.2%) | 0.12% -0.002 pp | 0.01% +0.003 pp | USD33.17 +12.8% | 8 qtrs — |
| 94 | CLARK ESTATES INC/NY | 67.3K +— (+0.0%) | 2.52M +663.6K (+35.8%) | 0.12% -0.002 pp | 0.61% +0.187 pp | USD32.58 +14.9% | 4 qtrs — |
| 95 | AURORA INVESTMENT COUNSEL | 66.1K +2.5K (+4.0%) | 2.47M +720.9K (+41.1%) | 0.11% +0.002 pp | 1.30% +0.382 pp | USD34.39 +8.8% | 5 qtrs — |
| 96 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 63.4K -84.8K (-57.2%) | 2.37M -1.7M (-41.9%) | 0.11% -0.149 pp | 0.00% 0.000 pp | USD29.41 +27.2% | 16 qtrs — |
| 97 | HUSSMAN STRATEGIC ADVISORS, INC. | 63.0K +21.0K (+50.0%) | 2.36M +1.2M (+103.7%) | 0.11% +0.035 pp | 0.57% +0.319 pp | USD36.29 +3.1% | 12 qtrs — |
| 98 | LOS ANGELES CAPITAL MANAGEMENT LLC | 66.6K -808.0 (-1.2%) | 1.92M +66.9K (+3.6%) | 0.11% -0.003 pp | 0.01% +0.000 pp | USD31.00 +20.7% | 13 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
18
Sells
18
Shares acquired
517.0K
Shares disposed
86.7K
Cash buys
—
Cash sales
2.00
Net activity
+430,295
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-07 | Zaeske Adam H. | Officer | M-Exempt | A | Common Stock | 7,500 | 0.00 | — | 7,500 | D | ↗ |
| 2026-04-02 | Ignelzi Troy A. | Director | A-Award | A | Stock Option | 17,710 | 27.74 | 491.3K | 17,710 | D | ↗ |
| 2026-04-02 | Anastasiou Peter | Officer | A-Award | A | Stock Option | 212,241 | 27.74 | 5.89M | 212,241 | D | ↗ |
| 2026-01-26 | Kapadia Sandip | Officer | S-Sale | D | Common Stock | 3,746 | 37.15 | 139.2K | 24,521 | D | ↗ |
| 2026-01-25 | Serafin Andrew | Officer | F-InKind | D | Common Stock | 1,126 | 36.82 | 41.5K | 1,474 | D | ↗ |
| 2026-01-25 | Kapadia Sandip | Officer | F-InKind | D | Common Stock | 2,553 | 36.82 | 94.0K | 2,172 | D | ↗ |
| 2026-01-25 | Dayno Jeffrey M. | Director / Officer | M-Exempt | D | Restricted Stock Units | 13,000 | 0.00 | — | 39,000 | D | ↗ |
| 2026-01-25 | Budur Kumar | Officer | M-Exempt | A | Common Stock | 2,662 | 0.00 | — | 2,662 | D | ↗ |
| 2026-01-24 | Serafin Andrew | Officer | F-InKind | D | Common Stock | 1,116 | 36.82 | 41.1K | 1,384 | D | ↗ |
| 2026-01-24 | Kapadia Sandip | Officer | M-Exempt | D | Restricted Stock Units | 3,813 | 0.00 | — | 7,625 | D | ↗ |
| 2026-01-24 | Dayno Jeffrey M. | Director / Officer | M-Exempt | D | Restricted Stock Units | 10,500 | 0.00 | — | 21,000 | D | ↗ |
| 2026-01-24 | Budur Kumar | Officer | F-InKind | D | Common Stock | 1,153 | 36.82 | 42.5K | 1,035 | D | ↗ |
| 2026-01-22 | Zaeske Adam H. | Officer | A-Award | A | Restricted Stock Units | 16,200 | 0.00 | — | 16,200 | D | ↗ |
| 2026-01-22 | Serafin Andrew | Officer | A-Award | A | Stock Option | 42,600 | 36.76 | 1.57M | 42,600 | D | ↗ |
| 2026-01-22 | Kapadia Sandip | Officer | A-Award | A | Restricted Stock Units | 12,200 | 0.00 | — | 12,200 | D | ↗ |
| 2026-01-22 | Dayno Jeffrey M. | Director / Officer | A-Award | A | Restricted Stock Units | 52,900 | 0.00 | — | 52,900 | D | ↗ |
| 2026-01-22 | Budur Kumar | Officer | A-Award | A | Restricted Stock Units | 12,200 | 0.00 | — | 12,200 | D | ↗ |
| 2026-01-15 | Kapadia Sandip | Officer | S-Sale | D | Common Stock | 20,961 | 35.92 | 752.8K | 0 | D | ↗ |
| 2025-12-12 | Dayno Jeffrey M. | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 8.22 | 164.4K | 20,000 | D | ↗ |
| 2025-12-05 | Kapadia Sandip | Officer | S-Sale | D | Common Stock | 20,000 | 39.54 | 790.9K | 0 | D | ↗ |
| 2025-11-21 | Kapadia Sandip | Officer | S-Sale | D | Common Stock | 3,427 | 35.00 | 119.9K | 0 | D | ↗ |
| 2025-09-30 | Kapadia Sandip | Officer | M-Exempt | D | Restricted Stock Units | 45,000 | 0.00 | — | 45,000 | D | ↗ |
| 2025-08-28 | Valor IV Pharma Holdings, LLC | 10% Owner | J-Other | D | Common Stock | 6,618,033 | 0.00 | — | 0 | D | ↗ |
| 2025-08-15 | Kapadia Sandip | Officer | S-Sale | D | Common Stock | 21,573 | 36.50 | 787.4K | 0 | D | ↗ |
| 2025-05-25 | Graf R. Mark | Director | A-Award | A | Stock Option | 14,522 | 34.23 | 497.1K | 14,522 | D | ↗ |
| 2025-05-15 | Szyper Linda M | Director | A-Award | A | Stock Option | 14,522 | 34.23 | 497.1K | 14,522 | D | ↗ |
| 2025-05-15 | Sender Gary | Director | A-Award | A | Stock Option | 14,522 | 34.23 | 497.1K | 14,522 | D | ↗ |
| 2025-05-15 | Sabater Juan A. | Director | A-Award | A | Stock Option | 14,522 | 34.23 | 497.1K | 14,522 | D | ↗ |
| 2025-05-15 | Philip Ron M | Director | A-Award | A | Stock Option | 14,522 | 34.23 | 497.1K | 14,522 | D | ↗ |
| 2025-05-15 | Gracias Antonio J. | Director | A-Award | A | Stock Option | 14,522 | 34.23 | 497.1K | 14,522 | D | ↗ |
| 2025-05-15 | Anastasiou Peter | Director | A-Award | A | Stock Option | 14,522 | 34.23 | 497.1K | 14,522 | D | ↗ |
| 2025-05-01 | Budur Kumar | Officer | M-Exempt | D | Restricted Stock Units | 18,750 | 0.00 | — | 18,750 | D | ↗ |
| 2025-04-07 | Zaeske Adam H. | Officer | A-Award | A | Stock Option | 100,000 | 28.40 | 2.84M | 100,000 | D | ↗ |
| 2025-04-02 | Philip Ron M | Director | A-Award | A | Stock Option | 14,077 | 32.53 | 457.9K | 14,077 | D | ↗ |
| 2025-04-01 | Kapadia Sandip | Officer | S-Sale | D | Common Stock | 6,247 | 32.48 | 202.9K | 740 | D | ↗ |
| 2025-03-29 | Kapadia Sandip | Officer | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | D | ↗ |
| 2025-03-03 | Dierks Jeffrey | Officer | M-Exempt | A | Common Stock | 4,869 | 8.22 | 40.0K | 4,869 | D | ↗ |
| 2025-01-27 | Kapadia Sandip | Officer | S-Sale | D | Common Stock | 1,775 | 38.05 | 67.5K | 0 | D | ↗ |
| 2025-01-27 | Dierks Jeffrey | Officer | S-Sale | D | Common Stock | 1,629 | 38.02 | 61.9K | 0 | D | ↗ |
| 2025-01-25 | Serafin Andrew | Officer | A-Award | A | Stock Option | 36,500 | 38.01 | 1.39M | 36,500 | D | ↗ |
| 2025-01-25 | Kapadia Sandip | Officer | A-Award | A | Restricted Stock Units | 18,900 | 0.00 | — | 18,900 | D | ↗ |
| 2025-01-25 | Dierks Jeffrey | Officer | A-Award | A | Restricted Stock Units | 13,450 | 0.00 | — | 13,450 | D | ↗ |
| 2025-01-25 | Dayno Jeffrey M. | Director / Officer | A-Award | A | Restricted Stock Units | 52,000 | 0.00 | — | 52,000 | D | ↗ |
| 2025-01-25 | Budur Kumar | Officer | A-Award | A | Restricted Stock Units | 10,650 | 0.00 | — | 10,650 | D | ↗ |
| 2025-01-24 | Serafin Andrew | Officer | M-Exempt | D | Restricted Stock Units | 2,500 | 0.00 | — | 7,500 | D | ↗ |
| 2025-01-24 | Kapadia Sandip | Officer | F-InKind | D | Common Stock | 2,037 | 38.01 | 77.4K | 1,775 | D | ↗ |
| 2025-01-24 | Dierks Jeffrey | Officer | M-Exempt | A | Common Stock | 13,125 | 30.69 | 402.8K | 13,125 | D | ↗ |
| 2025-01-24 | Dayno Jeffrey M. | Director / Officer | F-InKind | D | Common Stock | 4,567 | 38.01 | 173.6K | 5,933 | D | ↗ |
| 2025-01-24 | Budur Kumar | Officer | F-InKind | D | Common Stock | 1,151 | 38.01 | 43.7K | 1,036 | D | ↗ |
| 2025-01-21 | Kapadia Sandip | Officer | S-Sale | D | Common Stock | 25,000 | 40.18 | 1.00M | 0 | D | ↗ |
| 2025-01-21 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 1,123 | 33.44 | 37.6K | 5,615 | D | ↗ |
| 2025-01-21 | Dayno Jeffrey M. | Director / Officer | S-Sale | D | Common Stock | 19,293 | 40.13 | 774.2K | 0 | D | ↗ |
| 2025-01-16 | Dierks Jeffrey | Officer | M-Exempt | A | Common Stock | 29,475 | 33.44 | 985.6K | 29,475 | D | ↗ |
| 2025-01-15 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 10,507 | 33.44 | 351.4K | 36,213 | D | ↗ |
| 2025-01-13 | Dierks Jeffrey | Officer | M-Exempt | A | Common Stock | 7,180 | 33.44 | 240.1K | 7,180 | D | ↗ |
| 2024-11-05 | Valor IV Pharma Holdings, LLC | 10% Owner | S-Sale | D | Common Stock | 600,000 | 30.30 | 18.18M | 6,618,033 | D | ↗ |
| 2024-11-05 | Marshman Fund Trust II | 10% Owner | S-Sale | D | Common Stock | 600,000 | 30.30 | 18.18M | 6,051,120 | D | ↗ |
| 2024-11-01 | Valor IV Pharma Holdings, LLC | 10% Owner | S-Sale | D | Common Stock | 4,000,000 | 30.30 | 121.21M | 7,218,033 | D | ↗ |
| 2024-11-01 | Marshman Fund Trust II | 10% Owner | S-Sale | D | Common Stock | 4,000,000 | 30.30 | 121.21M | 6,651,120 | D | ↗ |
| 2024-10-29 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 21,496 | 24.00 | 515.9K | 28,972 | D | ↗ |
| 2024-10-01 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 400 | 24.00 | 9.6K | 50,468 | D | ↗ |
| 2024-09-30 | Kapadia Sandip | Officer | M-Exempt | A | Common Stock | 60,000 | 0.00 | — | 60,000 | D | ↗ |
| 2024-09-30 | Dierks Jeffrey | Officer | M-Exempt | A | Common Stock | 35,846 | 24.00 | 860.3K | 35,846 | D | ↗ |
| 2024-09-27 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 200 | 24.00 | 4.8K | 86,714 | D | ↗ |
| 2024-05-29 | Szyper Linda M | Director | A-Award | A | Stock Option | 6,336 | 29.33 | 185.8K | 6,336 | — | ↗ |
| 2024-05-29 | Sender Gary | Director | A-Award | A | Stock Option | 11,657 | 29.33 | 341.9K | 11,657 | — | ↗ |
| 2024-05-29 | Sabater Juan A. | Director | A-Award | A | Stock Option | 6,336 | 29.33 | 185.8K | 6,336 | — | ↗ |
| 2024-05-29 | Nielsen Jack | Director | A-Award | A | Stock Option | 6,336 | 29.33 | 185.8K | 6,336 | — | ↗ |
| 2024-05-29 | Graf R. Mark | Director | A-Award | A | Stock Option | 6,336 | 29.33 | 185.8K | 6,336 | — | ↗ |
| 2024-05-29 | Gracias Antonio J. | Director | A-Award | A | Stock Option | 8,870 | 29.33 | 260.2K | 8,870 | — | ↗ |
| 2024-05-29 | Anastasiou Peter | Director | A-Award | A | Stock Option | 6,336 | 29.33 | 185.8K | 6,336 | — | ↗ |
| 2024-05-01 | Budur Kumar | Officer | A-Award | A | Stock Option | 75,000 | 30.27 | 2.27M | 75,000 | — | ↗ |
| 2024-03-29 | Kapadia Sandip | Officer | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2024-03-15 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 9,644 | 8.22 | 79.3K | 4,869 | — | ↗ |
| 2024-03-08 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 94 | 8.22 | 772.68 | 14,513 | — | ↗ |
| 2024-01-24 | Serafin Andrew | Officer | A-Award | A | Restricted Stock Unit | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2024-01-24 | Kapadia Sandip | Officer | A-Award | A | Restricted Stock Units | 15,250 | 0.00 | — | 15,250 | — | ↗ |
| 2024-01-24 | Dierks Jeffrey | Officer | A-Award | A | Stock Option | 52,500 | 30.69 | 1.61M | 52,500 | — | ↗ |
| 2024-01-24 | Dayno Jeffrey M. | Director / Officer | A-Award | A | Restricted Stock Units | 42,000 | 0.00 | — | 42,000 | — | ↗ |
| 2024-01-24 | Budur Kumar | Officer | A-Award | A | Stock Option | 42,500 | 30.69 | 1.30M | 42,500 | — | ↗ |
| 2023-11-05 | Anastasiou Peter | Director | A-Award | A | Stock Option | 6,771 | 25.92 | 175.5K | 6,771 | — | ↗ |
| 2023-10-04 | Kapadia Sandip | Officer | A-Award | A | Restricted Stock Units | 150,000 | 31.78 | 4.77M | 150,000 | — | ↗ |
| 2023-10-04 | Dierks Jeffrey | Officer | A-Award | A | Restricted Stock Units | 150,000 | 31.78 | 4.77M | 150,000 | — | ↗ |
| 2023-05-26 | Dayno Jeffrey M. | Director / Officer | A-Award | A | Stock Option | 125,000 | 35.56 | 4.45M | 125,000 | — | ↗ |
| 2023-05-25 | Szyper Linda M | Director | A-Award | A | Stock Option | 5,224 | 35.99 | 188.0K | 15,693 | — | ↗ |
| 2023-05-25 | Sender Gary | Director | A-Award | A | Stock Option | 9,613 | 35.99 | 346.0K | 48,255 | — | ↗ |
| 2023-05-25 | Sabater Juan A. | Director | A-Award | A | Stock Option | 5,224 | 35.99 | 188.0K | 26,224 | — | ↗ |
| 2023-05-25 | Nielsen Jack | Director | A-Award | A | Stock Option | 5,224 | 35.99 | 188.0K | 26,224 | — | ↗ |
| 2023-05-25 | Graf R. Mark | Director | A-Award | A | Stock Option | 5,224 | 35.99 | 188.0K | 21,816 | — | ↗ |
| 2023-05-25 | Gracias Antonio J. | Director | A-Award | A | Stock Option | 7,314 | 35.99 | 263.2K | 36,714 | — | ↗ |
| 2023-05-01 | Budur Kumar | Officer | — | D | Common Stock | 0 | 0.00 | — | 1,005 | — | ↗ |
| 2023-03-29 | Kapadia Sandip | — | F-InKind | D | Common Stock | 15,414 | 33.36 | 514.2K | 14,586 | — | ↗ |
| 2022-12-14 | Wicki Andreas | Director | S-Sale | D | Common Stock | 130 | 60.00 | 7.8K | 2,147,943 | — | ↗ |
| 2022-12-14 | Nielsen Jack | Director | S-Sale | D | Common Stock | 2,834 | 59.96 | 169.9K | 2,571,024 | — | ↗ |
| 2022-12-13 | Wicki Andreas | Director | S-Sale | D | Common Stock | 6,320 | 60.13 | 380.0K | 2,148,073 | — | ↗ |
| 2022-12-12 | Wicki Andreas | Director | S-Sale | D | Common Stock | 22,391 | 60.36 | 1.35M | 2,154,393 | — | ↗ |
| 2022-12-09 | Nielsen Jack | Director | S-Sale | D | Common Stock | 9,847 | 59.89 | 589.7K | 2,573,858 | — | ↗ |
| 2022-12-08 | Nielsen Jack | Director | S-Sale | D | Common Stock | 36,878 | 59.90 | 2.21M | 2,583,705 | — | ↗ |
| 2022-12-07 | Nielsen Jack | Director | S-Sale | D | Common Stock | 64,026 | 60.35 | 3.86M | 2,620,583 | — | ↗ |
| 2022-12-05 | Wicki Andreas | Director | S-Sale | D | Common Stock | 77,853 | 61.23 | 4.77M | 2,176,784 | — | ↗ |
| 2022-12-02 | Serafin Andrew | Director / Officer | S-Sale | D | Common Stock | 37,080 | 60.12 | 2.23M | 920 | — | ↗ |
| 2022-12-01 | Nielsen Jack | Director | S-Sale | D | Common Stock | 65,652 | 60.00 | 3.94M | 2,684,609 | — | ↗ |
| 2022-11-30 | Nielsen Jack | Director | S-Sale | D | Common Stock | 42,667 | 58.93 | 2.51M | 2,750,261 | — | ↗ |
| 2022-11-29 | Nielsen Jack | Director | S-Sale | D | Common Stock | 21,333 | 57.82 | 1.23M | 2,792,928 | — | ↗ |
| 2022-11-22 | Nielsen Jack | Director | S-Sale | D | Common Stock | 31,902 | 57.60 | 1.84M | 2,814,261 | — | ↗ |
| 2022-11-21 | Nielsen Jack | Director | S-Sale | D | Common Stock | 24,898 | 57.08 | 1.42M | 2,846,163 | — | ↗ |
| 2022-11-18 | Nielsen Jack | Director | S-Sale | D | Common Stock | 20,800 | 57.00 | 1.19M | 2,871,061 | — | ↗ |
| 2022-11-15 | Wicki Andreas | Director | S-Sale | D | Common Stock | 10,961 | 60.10 | 658.8K | 2,254,637 | — | ↗ |
| 2022-11-15 | Nielsen Jack | Director | S-Sale | D | Common Stock | 62,933 | 56.80 | 3.57M | 2,891,861 | — | ↗ |
| 2022-11-14 | Wicki Andreas | Director | S-Sale | D | Common Stock | 40,317 | 59.10 | 2.38M | 2,265,598 | — | ↗ |
| 2022-11-14 | Nielsen Jack | Director | S-Sale | D | Common Stock | 58,667 | 58.70 | 3.44M | 2,954,794 | — | ↗ |
| 2022-11-11 | Nielsen Jack | Director | S-Sale | D | Common Stock | 36,800 | 57.14 | 2.10M | 3,013,461 | — | ↗ |
| 2022-11-10 | Wicki Andreas | Director | S-Sale | D | Common Stock | 95,242 | 58.80 | 5.60M | 2,305,915 | — | ↗ |
| 2022-11-09 | Wicki Andreas | Director | S-Sale | D | Common Stock | 15,301 | 58.05 | 888.2K | 2,401,157 | — | ↗ |
| 2022-11-08 | Wicki Andreas | Director | S-Sale | D | Common Stock | 18,865 | 60.01 | 1.13M | 2,416,458 | — | ↗ |
| 2022-11-04 | Wicki Andreas | Director | S-Sale | D | Common Stock | 157,950 | 58.81 | 9.29M | 2,435,323 | — | ↗ |
| 2022-11-03 | Wicki Andreas | Director | S-Sale | D | Common Stock | 254,141 | 59.44 | 15.11M | 2,593,273 | — | ↗ |
| 2022-11-03 | Dayno Jeffrey M. | Director / Officer | S-Sale | D | Common Stock | 15,000 | 60.02 | 900.3K | 0 | — | ↗ |
| 2022-11-02 | Wicki Andreas | Director | S-Sale | D | Common Stock | 164,676 | 58.81 | 9.68M | 2,847,414 | — | ↗ |
| 2022-11-01 | Dayno Jeffrey M. | Director / Officer | M-Exempt | D | Stock Option | 15,000 | 0.00 | — | 38,470 | — | ↗ |
| 2022-10-03 | Dierks Jeffrey | Director / Officer | M-Exempt | A | Common Stock | 12,173 | 8.22 | 100.1K | 12,173 | — | ↗ |
| 2022-08-22 | Dierks Jeffrey | Director / Officer | M-Exempt | D | Stock Option | 28,971 | 0.00 | — | 86,914 | — | ↗ |
| 2022-08-15 | Jacobs John C | Director | M-Exempt | D | Stock Option | 40,000 | 0.00 | — | 114,751 | — | ↗ |
| 2022-08-08 | Wicki Andreas | Director | S-Sale | D | Common Stock | 20,745 | 53.67 | 1.11M | 3,083,537 | — | ↗ |
| 2022-08-04 | Nielsen Jack | Director | S-Sale | D | Common Stock | 60,000 | 52.30 | 3.14M | 3,240,261 | — | ↗ |
| 2022-08-03 | Wicki Andreas | Director | S-Sale | D | Common Stock | 30,464 | 52.90 | 1.61M | 3,632,764 | — | ↗ |
| 2022-08-02 | Nielsen Jack | Director | S-Sale | D | Common Stock | 75,117 | 55.22 | 4.15M | 3,300,261 | — | ↗ |
| 2022-07-18 | Nielsen Jack | Director | S-Sale | D | Common Stock | 40,087 | 55.19 | 2.21M | 3,375,378 | — | ↗ |
| 2022-07-13 | Nielsen Jack | Director | S-Sale | D | Common Stock | 5,773 | 55.04 | 317.7K | 3,415,465 | — | ↗ |
| 2022-07-08 | Nielsen Jack | Director | S-Sale | D | Common Stock | 3,058 | 55.01 | 168.2K | 3,421,238 | — | ↗ |
| 2022-07-05 | Nielsen Jack | Director | S-Sale | D | Common Stock | 87,417 | 55.26 | 4.83M | 3,612,844 | — | ↗ |
| 2022-06-29 | Nielsen Jack | Director | S-Sale | D | Common Stock | 11,038 | 52.04 | 574.4K | 3,732,747 | — | ↗ |
| 2022-06-24 | Nielsen Jack | Director | S-Sale | D | Common Stock | 2,726 | 52.10 | 142.0K | 3,747,318 | — | ↗ |
| 2022-06-15 | Jacobs John C | Officer | M-Exempt | D | Stock Option | 15,000 | 0.00 | — | 154,751 | — | ↗ |
| 2022-06-13 | Jacobs John C | Officer | M-Exempt | D | Stock Option | 25,000 | 0.00 | — | 169,751 | — | ↗ |
| 2022-05-20 | Szyper Linda M | Director | A-Award | A | Stock Option | 4,742 | 0.00 | — | 4,742 | — | ↗ |
| 2022-05-20 | Sender Gary | Director | A-Award | A | Stock Option | 8,726 | 41.33 | 360.6K | 8,726 | — | ↗ |
| 2022-05-20 | Sabater Juan A. | Director | A-Award | A | Stock Option | 4,742 | 41.33 | 196.0K | 4,742 | — | ↗ |
| 2022-05-20 | Nielsen Jack | Director | A-Award | A | Stock Option | 4,742 | 0.00 | — | 4,742 | — | ↗ |
| 2022-05-20 | Graf R. Mark | Director | A-Award | A | Stock Option | 4,742 | 0.00 | — | 4,742 | — | ↗ |
| 2022-05-20 | Gracias Antonio J. | Director | A-Award | A | Stock Option | 6,639 | 0.00 | — | 6,639 | — | ↗ |
| 2022-04-21 | Nielsen Jack | Director | S-Sale | D | Common Stock | 6,554 | 52.19 | 342.1K | 3,847,781 | — | ↗ |
| 2022-04-18 | Nielsen Jack | Director | S-Sale | D | Common Stock | 97,886 | 52.35 | 5.12M | 3,884,512 | — | ↗ |
| 2022-04-12 | Nielsen Jack | Director | S-Sale | D | Common Stock | 2,486 | 50.05 | 124.4K | 10,741 | — | ↗ |
| 2022-04-07 | Nielsen Jack | Director | S-Sale | D | Common Stock | 4,610 | 50.25 | 231.7K | 4,098,359 | — | ↗ |
| 2022-04-04 | Nielsen Jack | Director | S-Sale | D | Common Stock | 899 | 50.00 | 45.0K | 4,120,798 | — | ↗ |
| 2022-04-01 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 14,471 | 0.00 | — | 116,085 | — | ↗ |
| 2022-03-30 | Nielsen Jack | Director | S-Sale | D | Common Stock | 3,470 | 50.24 | 174.3K | 18,473 | — | ↗ |
| 2022-03-25 | Nielsen Jack | Director | S-Sale | D | Common Stock | 4,514 | 50.24 | 226.8K | 31,649 | — | ↗ |
| 2022-03-24 | ARONIN JEFFREY S | Director | A-Award | D | Stock Option | 1,180,599 | 50.19 | 59.25M | 1,180,599 | — | ↗ |
| 2022-03-22 | Nielsen Jack | Director | S-Sale | D | Common Stock | 2,359 | 50.12 | 118.2K | 36,163 | — | ↗ |
| 2022-03-17 | Nielsen Jack | Director | S-Sale | D | Common Stock | 1,282 | 50.10 | 64.2K | 40,685 | — | ↗ |
| 2022-03-16 | Jacobs John C | Officer | M-Exempt | D | Stock Option | 15,000 | 0.00 | — | 194,751 | — | ↗ |
| 2022-03-14 | Jacobs John C | Officer | S-Sale | D | Common Stock | 11,614 | 42.66 | 495.5K | 930 | — | ↗ |
| 2022-03-09 | Wicki Andreas | Director | S-Sale | D | Common Stock | 75,217 | 45.80 | 3.44M | 3,733,598 | — | ↗ |
| 2022-03-03 | Wicki Andreas | Director | S-Sale | D | Common Stock | 175,000 | 41.01 | 7.18M | 3,948,815 | — | ↗ |
| 2022-03-02 | Wicki Andreas | Director | S-Sale | D | Common Stock | 328,927 | 40.52 | 13.33M | 4,123,815 | — | ↗ |
| 2022-03-01 | Wicki Andreas | Director | S-Sale | D | Common Stock | 92,501 | 40.24 | 3.72M | 4,452,742 | — | ↗ |
| 2022-03-01 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 4,869 | 8.22 | 40.0K | 14,607 | — | ↗ |
| 2022-02-28 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 10,041 | 24.00 | 241.0K | 130,556 | — | ↗ |
| 2022-02-17 | Dierks Jeffrey | Officer | M-Exempt | A | Common Stock | 200 | 24.00 | 4.8K | 200 | — | ↗ |
| 2022-02-16 | Dierks Jeffrey | Officer | S-Sale | D | Common Stock | 4,259 | 40.05 | 170.6K | 0 | — | ↗ |
| 2022-01-06 | Dierks Jeffrey | Director / Officer | M-Exempt | D | Stock Option | 3,690 | 8.22 | 30.3K | 9,739 | — | ↗ |
| 2022-01-04 | Jacobs John C | Director / Officer | M-Exempt | D | Stock Option | 18,053 | 8.22 | 148.4K | 234,751 | — | ↗ |
| 2022-01-03 | Jacobs John C | Director / Officer | M-Exempt | A | Common Stock | 10,647 | 8.22 | 87.5K | 10,647 | — | ↗ |
| 2021-12-27 | Jacobs John C | Director / Officer | M-Exempt | D | Stock Option | 1,300 | 8.22 | 10.7K | 263,451 | — | ↗ |
| 2021-12-14 | ARONIN JEFFREY S | Director | M-Exempt | A | Stock Option | 251,922 | 24.00 | 6.05M | 1,007,689 | — | ↗ |
| 2021-12-13 | Jacobs John C | Director / Officer | S-Sale | D | Common Stock | 13,140 | 38.02 | 499.6K | 11,860 | — | ↗ |
| 2021-12-10 | Wicki Andreas | Director | S-Sale | D | Common Stock | 2,585 | 40.08 | 103.6K | 4,545,243 | — | ↗ |
| 2021-12-08 | Wicki Andreas | Director | S-Sale | D | Common Stock | 24,683 | 40.09 | 989.5K | 4,547,828 | — | ↗ |
| 2021-11-18 | Szyper Linda M | Director | A-Award | A | Stock Option | 5,727 | 21.82 | 125.0K | 5,727 | — | ↗ |
| 2021-11-17 | Wicki Andreas | Director | S-Sale | D | Common Stock | 1,417 | 41.25 | 58.5K | 4,572,511 | — | ↗ |
| 2021-11-16 | Wicki Andreas | Director | S-Sale | D | Common Stock | 32,251 | 41.09 | 1.33M | 4,573,928 | — | ↗ |
| 2021-11-15 | Wicki Andreas | Director | S-Sale | D | Common Stock | 35,600 | 42.08 | 1.50M | 4,609,179 | — | ↗ |
| 2021-11-01 | Dierks Jeffrey | Officer | M-Exempt | A | Common Stock | 10,000 | 8.22 | 82.2K | 10,000 | — | ↗ |
| 2021-10-19 | Dayno Jeffrey M. | Officer | M-Exempt | A | Common Stock | 14,099 | 8.22 | 115.9K | 14,099 | — | ↗ |
| 2021-10-06 | Dayno Jeffrey M. | Officer | M-Exempt | A | Common Stock | 1,800 | 8.22 | 14.8K | 1,800 | — | ↗ |
| 2021-09-13 | Jacobs John C | Director / Officer | M-Exempt | D | Stock Option | 25,000 | 8.22 | 205.5K | 289,751 | — | ↗ |
| 2021-09-07 | Dierks Jeffrey | Officer | S-Sale | D | Common Stock | 5,000 | 37.00 | 185.0K | 0 | — | ↗ |
| 2021-09-07 | Dayno Jeffrey M. | Officer | S-Sale | D | Common Stock | 10,000 | 37.58 | 375.8K | 0 | — | ↗ |
| 2021-09-01 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 10,000 | 8.22 | 82.2K | 18,692 | — | ↗ |
| 2021-08-27 | Dierks Jeffrey | Officer | S-Sale | D | Common Stock | 3,400 | 35.18 | 119.6K | 0 | — | ↗ |
| 2021-08-27 | Dayno Jeffrey M. | Officer | S-Sale | D | Common Stock | 7,841 | 35.16 | 275.7K | 0 | — | ↗ |
| 2021-08-26 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 1,600 | 8.22 | 13.2K | 32,092 | — | ↗ |
| 2021-08-26 | Dayno Jeffrey M. | Officer | M-Exempt | A | Common Stock | 2,159 | 8.22 | 17.7K | 2,159 | — | ↗ |
| 2021-08-10 | Dayno Jeffrey M. | Officer | M-Exempt | D | Stock Option | 9,950 | 8.22 | 81.8K | 93,469 | — | ↗ |
| 2021-07-22 | Dayno Jeffrey M. | Officer | M-Exempt | A | Common Stock | 50 | 8.22 | 411.00 | 50 | — | ↗ |
| 2021-06-15 | Dierks Jeffrey | Officer | M-Exempt | D | Stock Option | 15,000 | 8.22 | 123.3K | 33,692 | — | ↗ |
| 2021-06-01 | Dierks Jeffrey | Officer | A-Award | A | Stock Option | 53,900 | 33.44 | 1.80M | 53,900 | — | ↗ |
| 2021-05-20 | Sender Gary | Director | A-Award | A | Stock Option | 13,333 | 32.50 | 433.3K | 13,333 | — | ↗ |
| 2021-05-20 | Sabater Juan A. | Director | A-Award | A | Stock Option | 7,246 | 32.50 | 235.5K | 7,246 | — | ↗ |
| 2021-05-20 | Nielsen Jack | Director | A-Award | A | Stock Option | 7,246 | 32.50 | 235.5K | 7,246 | — | ↗ |
| 2021-05-20 | Motley Eric L | Director | A-Award | A | Stock Option | 7,246 | 32.50 | 235.5K | 7,246 | — | ↗ |
| 2021-05-20 | Graf R. Mark | Director | A-Award | A | Stock Option | 7,246 | 32.50 | 235.5K | 7,246 | — | ↗ |
| 2021-05-20 | Gracias Antonio J. | Director | A-Award | A | Stock Option | 10,144 | 32.50 | 329.7K | 10,144 | — | ↗ |
| 2021-03-29 | Kapadia Sandip | Officer | A-Award | A | Stock Option | 230,000 | 29.03 | 6.68M | 230,000 | — | ↗ |
| 2020-11-11 | Motley Eric L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-11-11 | Graf R. Mark | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-08-26 | Nielsen Jack | Director | P-Purchase | A | Common Stock | 3,922 | 34.30 | 134.5K | 42,702 | — | ↗ |
| 2020-08-25 | Nielsen Jack | Director | P-Purchase | A | Common Stock | 823 | 34.20 | 28.1K | 38,780 | — | ↗ |
Executive team
Top executives
EBIT / Employee
857.1K
Shares Outstanding
57.87M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jeffrey M. Dayno, M.D. President and Chief Executive Officer | 743.6K | — | 1.98M | 4.60M | 558.0K | 22.4K | 7.90M | 83.24% | ↗ |
| 2 | 2025 | Adam Zaeske EVP and Chief Commercial Officer | 376.9K | 200.0K | 852.0K | 1.87M | 189.0K | 180.3K | 3.66M | 74.18% | ↗ |
| 3 | 2025 | Sandip Kapadia EVP and Chief Financial Officer and Chief Administrative Officer | 522.8K | — | 718.4K | 1.69M | 248.3K | 22.1K | 3.20M | 75.24% | ↗ |
| 4 | 2025 | Jeffrey Dierks Former EVP and Chief Commercial Officer | 132.3K | — | 511.2K | 1.21M | — | 497.5K | 2.35M | 73.17% | ↗ |
| 5 | 2025 | Kumar Budur EVP and Chief Medical & Scientific Officer | 598.0K | — | 404.8K | 955.6K | 299.0K | 22.1K | 2.28M | 59.68% | ↗ |
| 6 | 2025 | Andrew Serafin EVP, Chief Strategy Officer | 439.2K | — | 395.3K | 932.6K | 219.6K | 22.6K | 2.01M | 66.09% | ↗ |
| 7 | 2024 | Jeffrey M. Dayno, M.D. President and Chief Executive Officer | 715.0K | 300.0K | 1.29M | 4.19M | 637.0K | 14.7K | 7.15M | 76.67% | ↗ |
| 8 | 2024 | Jeffrey Dayno President and Chief Executive Officer | 715.0K | 300.0K | 1.29M | 4.19M | 637.0K | 14.7K | 7.15M | 76.67% | ↗ |
| 9 | 2024 | Kumar Budur EVP and Chief Medical & Scientific Officer | 555.1K | — | 2.54M | 2.42M | 207.0K | 11.6K | 5.73M | 86.50% | ↗ |
| 10 | 2024 | Sandip Kapadia EVP and Chief Financial Officer and Chief Administrative Officer | 507.6K | 250.0K | 468.0K | 1.54M | 291.9K | 14.8K | 3.07M | 65.34% | ↗ |
| 11 | 2024 | Jeffrey Dierks EVP and Chief Commercial Officer | 508.7K | 250.0K | 329.9K | 1.09M | 279.9K | 14.9K | 2.47M | 57.36% | ↗ |
| 12 | 2024 | Jeffrey Dierks Former EVP and Chief Commercial Officer | 508.7K | 250.0K | 329.9K | 1.09M | 279.9K | 14.9K | 2.47M | 57.36% | ↗ |
| 13 | 2024 | Andrew Serafin EVP, Chief Strategy Officer | 420.3K | 125.0K | 306.9K | 989.1K | 231.3K | 14.8K | 2.09M | 62.09% | ↗ |
| 14 | 2023 | Jeffrey Dierks EVP and Chief Commercial Officer | 486.8K | 50.0K | 4.77M | — | 279.9K | 14.0K | 5.60M | 85.16% | ↗ |
| 15 | 2023 | Jeffrey Dierks Former EVP and Chief Commercial Officer | 486.8K | 50.0K | 4.77M | — | 279.9K | 14.0K | 5.60M | 85.16% | ↗ |
| 16 | 2023 | Sandip Kapadia EVP and Chief Financial Officer and Chief Administrative Officer | 507.6K | — | 4.77M | — | 291.9K | 14.0K | 5.58M | 85.42% | ↗ |
| 17 | 2023 | Jeffrey M. Dayno, M.D. President and Chief Executive Officer | 612.5K | 200.0K | — | 3.19M | 437.0K | 13.9K | 4.45M | 71.61% | ↗ |
| 18 | 2023 | Jeffrey Dayno President and Chief Executive Officer | 612.5K | 200.0K | — | 3.19M | 437.0K | 13.9K | 4.45M | 71.61% | ↗ |
| 19 | 2023 | Kumar Budur EVP and Chief Medical Officer | 440.3K | 100.0K | — | — | 207.0K | 13.5K | 760.8K | 0.00% | ↗ |
| 20 | 2023 | Kumar Budur EVP and Chief Medical & Scientific Officer | 440.3K | 100.0K | — | — | 207.0K | 13.5K | 760.8K | 0.00% | ↗ |
| 21 | 2023 | Andrew Serafin EVP, Chief Strategy Officer | 402.2K | — | — | — | 231.3K | 14.0K | 647.4K | 0.00% | ↗ |
| 22 | 2023 | John C. Jacobs Former President and Former Chief Executive Officer | 29.6K | — | — | — | — | 7.1K | 36.6K | 0.00% | ↗ |
| 23 | 2022 | Sandip Kapadia EVP and Chief Financial Officer and Chief Administrative Officer | 476.6K | 175.0K | — | — | 297.9K | 13.1K | 962.6K | 0.00% | ↗ |
| 24 | 2022 | Sandip Kapadia EVP and Chief Financial Officer | 476.6K | 175.0K | — | — | 297.9K | 13.1K | 962.6K | 0.00% | ↗ |
| 25 | 2022 | Jeffrey Dayno President and Chief Executive Officer | 459.0K | — | — | — | 286.9K | 16.3K | 762.2K | 0.00% | ↗ |
| 26 | 2022 | Jeffrey Dayno Chief Medical Officer | 459.0K | — | — | — | 286.9K | 16.3K | 762.2K | 0.00% | ↗ |
| 27 | 2022 | Jeffrey Dierks EVP and Chief Commercial Officer | 412.1K | — | — | — | 236.9K | 13.1K | 662.1K | 0.00% | ↗ |
| 28 | 2022 | Andrew Serafin EVP, Chief Strategy Officer | 375.7K | — | — | — | 216.0K | 13.7K | 605.4K | 0.00% | ↗ |
| 29 | 2022 | John C. Jacobs Former President and Former Chief Executive Officer | 500.9K | — | — | — | — | 13.9K | 514.8K | 0.00% | ↗ |
| 30 | 2022 | John C. Jacobs President and Chief Executive Officer | 500.9K | — | — | — | — | 13.9K | 514.8K | 0.00% | ↗ |
| 31 | 2021 | Sandip Kapadia EVP and Chief Financial Officer and Chief Administrative Officer | 354.2K | 175.0K | 1.74M | 3.77M | 185.3K | 2.6K | 6.22M | 88.48% | ↗ |
| 32 | 2021 | Sandip Kapadia EVP and Chief Financial Officer | 354.2K | 175.0K | 1.74M | 3.77M | 185.3K | 2.6K | 6.22M | 88.48% | ↗ |
| 33 | 2021 | Jeffrey Dierks EVP and Chief Commercial Officer | 308.7K | 172.9K | — | 2.22M | — | 878.00 | 2.70M | 82.14% | ↗ |
| 34 | 2021 | John C. Jacobs President and Chief Executive Officer | 488.7K | — | — | — | 384.8K | 12.0K | 885.6K | 0.00% | ↗ |
| 35 | 2021 | John C. Jacobs Former President and Former Chief Executive Officer | 488.7K | — | — | — | 384.8K | 12.0K | 885.6K | 0.00% | ↗ |
| 36 | 2021 | Jeffrey Dayno EVP and Chief Medical Officer | 445.6K | — | — | — | 245.1K | 12.0K | 702.7K | 0.00% | ↗ |
| 37 | 2021 | Jeffrey Dayno Chief Medical Officer | 445.6K | — | — | — | 245.1K | 12.0K | 702.7K | 0.00% | ↗ |
| 38 | 2021 | Jeffrey Dayno President and Chief Executive Officer | 445.6K | — | — | — | 245.1K | 12.0K | 702.2K | 0.00% | ↗ |
| 39 | 2021 | Andrew Serafin EVP, Chief Strategy Officer | 366.5K | — | — | — | 192.4K | 12.0K | 570.9K | 0.00% | ↗ |
| 40 | 2021 | Andrew Serafin EVP and Chief Strategy Officer | 366.5K | — | — | — | 192.4K | 12.0K | 570.9K | 0.00% | ↗ |
| 41 | 2021 | Susan Drexler Former SVP and Chief Financial Officer | 83.1K | — | — | — | — | 285.4K | 368.5K | 0.00% | ↗ |
| 42 | 2020 | John C. Jacobs President and Chief Executive Officer | 473.1K | 460.0K | — | 2.30M | — | 835.00 | 3.23M | 71.08% | ↗ |
| 43 | 2020 | Jeffrey Dayno Chief Medical Officer | 431.4K | 302.0K | — | 1.97M | — | 885.00 | 2.70M | 72.82% | ↗ |
| 44 | 2020 | Jeffrey Dayno EVP and Chief Medical Officer | 431.4K | 302.0K | — | 1.97M | — | 885.00 | 2.70M | 72.82% | ↗ |
| 45 | 2020 | Jeffrey Dierks Chief Commercial Officer | 308.7K | 172.9K | — | 2.22M | — | 878.00 | 2.70M | 82.14% | ↗ |
| 46 | 2020 | Jeffrey Dierks EVP and Chief Commercial Officer | 308.7K | 172.9K | — | 2.22M | — | 878.00 | 2.70M | 82.14% | ↗ |
| 47 | 2019 | John C. Jacobs President and Chief Executive Officer | 454.0K | 391.6K | — | — | — | 88.00 | 845.7K | 0.00% | ↗ |
| 48 | 2019 | Jeffrey Dayno EVP and Chief Medical Officer | 414.0K | 238.1K | — | 20.0K | — | 148.00 | 672.2K | 2.98% | ↗ |
| 49 | 2019 | Jeffrey Dayno Chief Medical Officer | 414.0K | 238.1K | — | 20.0K | — | 148.00 | 198.00 | 10,101.01% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jeffrey Dayno | President, Chief Executive Officer & Director | 1M | — |
| Sandip S. Kapadia | Executive Vice President, Chief Administrative Officer & Chief Financial Officer | 1M | male |
| Adam Zaeske | Executive Vice President & Chief Commercial Officer | 946.2K | male |
| Kumar Budur | Executive Vice President and Chief Medical & Scientific Officer | 919.1K | — |
| Andrew Serafin | Executive Vice President & Chief Strategy Officer | 681.4K | male |
| Jeffrey S. Aronin | Founder & Non-Executive Chairman | 77.5K | male |
| Peter Anastasiou | Chief Operating Officer | 58.3K | male |
| Tricia Glover | Chief Compliance Officer | — | female |
| Audrey Murphy | Chief Human Resources Officer | — | female |
| Brennan Doyle | Vice President & Head of Investor Relations | — | — |
| Cate McCanless | Senior Vice President & Chief Corporate Affairs Officer | — | female |
| Christian Ulrich | Executive VP, General Counsel & Corporate Secretary | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HRMY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
